{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:49:28Z","timestamp":1792100968580,"version":"4.4.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1614,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1124\/jpet.120.265181","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T19:15:14Z","timestamp":1591125314000},"page":"342-353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease"],"prefix":"10.1016","volume":"374","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4102-6023","authenticated-orcid":false,"given":"Ughetta","family":"del Balzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre E.","family":"Signore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Walkinshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd W.","family":"Seeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell C.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingjian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Arend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee A.","family":"Flippin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Aisha","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Gervasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian H.","family":"Kjaergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Langsetmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkmar","family":"Guenzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Y.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve J.","family":"Klaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.","family":"Neff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.120.265181_bib1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1053\/j.ackd.2008.12.009","article-title":"Hyporesponsiveness to erythropoiesis stimulating agents in chronic kidney disease: the many faces of inflammation","volume":"16","author":"Adamson","year":"2009","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1124\/jpet.120.265181_bib2","doi-asserted-by":"crossref","first-page":"19533","DOI":"10.1074\/jbc.M111.238667","article-title":"Intestinal hypoxia-inducible factor-2\u03b1 (HIF-2\u03b1) is critical for efficient erythropoiesis","volume":"286","author":"Anderson","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.120.265181_bib3","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.120.265181_bib4","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/mol.110.070508","article-title":"Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitor","volume":"79","author":"Barrett","year":"2011","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.120.265181_bib5","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1111\/bph.13188","article-title":"Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats","volume":"172","author":"Barrett","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.120.265181_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/1091581817737232","article-title":"Evaluation of the carcinogenic potential of roxadustat (FG-4592), a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase in CD-1 mice and Sprague Dawley rats","volume":"36","author":"Beck","year":"2017","journal-title":"Int J Toxicol"},{"key":"10.1124\/jpet.120.265181_bib7","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1681\/ASN.2015030241","article-title":"Roxadustat (FG-4592): correction of anemia in incident dialysis patients","volume":"27","author":"Besarab","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/jpet.120.265181_bib8","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/jpet.120.265181_bib9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.23876\/j.krcp.2017.36.3.209","article-title":"Treatment of renal anemia: erythropoiesis stimulating agents and beyond","volume":"36","author":"Biggar","year":"2017","journal-title":"Kidney Res Clin Pract"},{"key":"10.1124\/jpet.120.265181_bib10","doi-asserted-by":"crossref","first-page":"a011619","DOI":"10.1101\/cshperspect.a011619","article-title":"Erythropoietin","volume":"3","author":"Bunn","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1124\/jpet.120.265181_bib11","doi-asserted-by":"crossref","first-page":"20661","DOI":"10.1074\/jbc.M116.749291","article-title":"Tuning the transcriptional response to hypoxia by inhibiting hypoxia-inducible factor (HIF) prolyl and asparaginyl hydroxylases","volume":"291","author":"Chan","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.120.265181_bib12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.120.265181_bib13","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.120.265181_bib14","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1158\/0008-5472.CAN-05-4564","article-title":"The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha","volume":"66","author":"Dayan","year":"2006","journal-title":"Cancer Res"},{"key":"10.1124\/jpet.120.265181_bib15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/ndt\/gfg560","article-title":"Hepcidin: a molecular link between inflammation and anaemia","volume":"19","author":"Deicher","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/jpet.120.265181_bib16","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/13543784.2018.1493455","article-title":"Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease","volume":"27","author":"Del Vecchio","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/jpet.120.265181_bib17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1471-2369-14-74","article-title":"Pathophysiology and treatment of focal segmental glomerulosclerosis: the role of animal models","volume":"14","author":"de Mik","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1124\/jpet.120.265181_bib18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40265-019-01077-1","article-title":"Roxadustat: first global approval","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"10.1124\/jpet.120.265181_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2215\/CJN.00630208","article-title":"Health-related quality of life and hemoglobin levels in chronic kidney disease patients","volume":"4","author":"Finkelstein","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/jpet.120.265181_bib20","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/cdd.2008.10","article-title":"Role and regulation of prolyl hydroxylase domain proteins","volume":"15","author":"Fong","year":"2008","journal-title":"Cell Death Differ"},{"key":"10.1124\/jpet.120.265181_bib21","doi-asserted-by":"crossref","first-page":"e0124048","DOI":"10.1371\/journal.pone.0124048","article-title":"Iron-hepcidin dysmetabolism, anemia and renal hypoxia, inflammation and fibrosis in the remnant kidney rat model","volume":"10","author":"Garrido","year":"2015","journal-title":"PLoS One"},{"key":"10.1124\/jpet.120.265181_bib22","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD","volume":"69","author":"Gupta","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/jpet.120.265181_bib23","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1152\/ajprenal.00174.2010","article-title":"Hypoxic regulation of erythropoiesis and iron metabolism","volume":"299","author":"Haase","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/jpet.120.265181_bib24","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1096\/fj.04-3399fje","article-title":"Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway","volume":"19","author":"Hirsil\u00e4","year":"2005","journal-title":"FASEB J"},{"key":"10.1124\/jpet.120.265181_bib25","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1749-6632.1994.tb55728.x","article-title":"Inhibition of erythropoietin production by cytokines. Implications for the anemia involved in inflammatory states","volume":"718","author":"Jelkmann","year":"1994","journal-title":"Ann N Y Acad Sci"},{"key":"10.1124\/jpet.120.265181_bib26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1146\/annurev.biochem.74.082803.133142","article-title":"Proline hydroxylation and gene expression","volume":"74","author":"Kaelin","year":"2005","journal-title":"Annu Rev Biochem"},{"key":"10.1124\/jpet.120.265181_bib27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","article-title":"Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway","volume":"30","author":"Kaelin","year":"2008","journal-title":"Mol Cell"},{"key":"10.1124\/jpet.120.265181_bib28","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1182\/blood-2010-02-270322","article-title":"Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia","volume":"116","author":"Kapitsinou","year":"2010","journal-title":"Blood"},{"key":"10.1124\/jpet.120.265181_bib29","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2013-06-508325","article-title":"A systematic analysis of global anemia burden from 1990 to 2010","volume":"123","author":"Kassebaum","year":"2014","journal-title":"Blood"},{"key":"10.1124\/jpet.120.265181_bib30","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1096\/fj.02-0168fje","article-title":"Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-kappaB","volume":"16","author":"La Ferla","year":"2002","journal-title":"FASEB J"},{"key":"10.1124\/jpet.120.265181_bib31","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1101\/gad.991402","article-title":"FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor","volume":"16","author":"Lando","year":"2002","journal-title":"Genes Dev"},{"key":"10.1124\/jpet.120.265181_bib32","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1126\/science.1068592","article-title":"Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch","volume":"295","author":"Lando","year":"2002","journal-title":"Science"},{"key":"10.1124\/jpet.120.265181_bib33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000455166","article-title":"Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients","volume":"45","author":"Locatelli","year":"2017","journal-title":"Am J Nephrol"},{"issue":"Suppl 3","key":"10.1124\/jpet.120.265181_bib34","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2362.2005.01528.x","article-title":"Hyporesponsiveness to erythropoietic therapy due to chronic inflammation","volume":"35","author":"Macdougall","year":"2005","journal-title":"Eur J Clin Invest"},{"key":"10.1124\/jpet.120.265181_bib35","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1128\/MCB.01927-06","article-title":"Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells","volume":"27","author":"MacKenzie","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1124\/jpet.120.265181_bib36","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1101\/gad.924501","article-title":"FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity","volume":"15","author":"Mahon","year":"2001","journal-title":"Genes Dev"},{"key":"10.1124\/jpet.120.265181_bib37","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2011-09-380337","article-title":"Deletion of HIF-2\u03b1 in the enterocytes decreases the severity of tissue iron loading in hepcidin knockout mice","volume":"119","author":"Mastrogiannaki","year":"2012","journal-title":"Blood"},{"key":"10.1124\/jpet.120.265181_bib38","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1172\/JCI38499","article-title":"HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice","volume":"119","author":"Mastrogiannaki","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.120.265181_bib39","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/apha.12096","article-title":"Prolyl 4-hydroxylases, master regulators of the hypoxia response","volume":"208","author":"Myllyharju","year":"2013","journal-title":"Acta Physiol (Oxf)"},{"key":"10.1124\/jpet.120.265181_bib40","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3181\/00379727-112-28182","article-title":"Relation between erythropoietin plasma level and oxygen requirements","volume":"112","author":"Naets","year":"1963","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1124\/jpet.120.265181_bib41","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0022-3565(24)37480-4","article-title":"Efflux of intracellular alpha-ketoglutarate via p-aminohippurate\/dicarboxylate exchange in OK kidney epithelial cells","volume":"285","author":"Nagai","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.265181_bib42","first-page":"86","article-title":"Familial erythrocytosis arising from a gain-of-function mutation in the HIF2A gene of the oxygen sensing pathway","volume":"77","author":"Percy","year":"2008","journal-title":"Ulster Med J"},{"key":"10.1124\/jpet.120.265181_bib43","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4161\/cc.7.1.5145","article-title":"Role of the hypoxia inducible factors HIF in iron metabolism","volume":"7","author":"Peyssonnaux","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1124\/jpet.120.265181_bib44","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.120.265181_bib45","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3181\/00379727-106-26383","article-title":"Effect of hypoxia on plasma erythropoietin in the rabbit","volume":"106","author":"Prentice","year":"1961","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1124\/jpet.120.265181_bib46","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2215\/CJN.06890615","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD","volume":"11","author":"Provenzano","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1124\/jpet.120.265181_bib47","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/jpet.120.265181_bib48","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1172\/JCI30117","article-title":"Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo","volume":"117","author":"Rankin","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.120.265181_bib49","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.biochi.2016.03.012","article-title":"Pathological and molecular mechanisms underlying resistance to recombinant human erythropoietin therapy in the remnant kidney rat model of chronic kidney disease associated anemia","volume":"125","author":"Ribeiro","year":"2016","journal-title":"Biochimie"},{"key":"10.1124\/jpet.120.265181_bib50","doi-asserted-by":"crossref","first-page":"20055","DOI":"10.1074\/jbc.272.32.20055","article-title":"Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1","volume":"272","author":"Rolfs","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.120.265181_bib51","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1128\/iai.57.4.1177-1185.1989","article-title":"Protracted anemia associated with chronic, relapsing systemic inflammation induced by arthropathic peptidoglycan-polysaccharide polymers in rats","volume":"57","author":"Sartor","year":"1989","journal-title":"Infect Immun"},{"key":"10.1124\/jpet.120.265181_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/HP.S130526","article-title":"Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer","volume":"5","author":"Seeley","year":"2017","journal-title":"Hypoxia (Auckl)"},{"key":"10.1124\/jpet.120.265181_bib53","first-page":"5447","article-title":"A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation","volume":"12","author":"Semenza","year":"1992","journal-title":"Mol Cell Biol"},{"key":"10.1124\/jpet.120.265181_bib54","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cmet.2008.12.012","article-title":"Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency","volume":"9","author":"Shah","year":"2009","journal-title":"Cell Metab"},{"key":"10.1124\/jpet.120.265181_bib55","doi-asserted-by":"crossref","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States","volume":"9","author":"Stauffer","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/jpet.120.265181_bib56","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-\u03b1 dose and achieved hemoglobin outcomes","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.120.265181_bib57","doi-asserted-by":"crossref","first-page":"24142","DOI":"10.1074\/jbc.274.34.24142","article-title":"Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation","volume":"274","author":"Tacchini","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.120.265181_bib58","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.pop.2008.01.008","article-title":"Chronic kidney disease and its complications","volume":"35","author":"Thomas","year":"2008","journal-title":"Prim Care"},{"key":"10.1124\/jpet.120.265181_bib59","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1440-1797.2008.01065.x","article-title":"Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease","volume":"14","author":"Thorp","year":"2009","journal-title":"Nephrology (Carlton)"},{"key":"10.1124\/jpet.120.265181_bib60","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1101\/gad.11.1.72","article-title":"Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells","volume":"11","author":"Tian","year":"1997","journal-title":"Genes Dev"},{"key":"10.1124\/jpet.120.265181_bib61","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.120.265181_bib62","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1074\/jbc.270.3.1230","article-title":"Purification and characterization of hypoxia-inducible factor 1","volume":"270","author":"Wang","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.120.265181_bib63","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1039\/C7SC02103H","article-title":"Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials","volume":"8","author":"Yeh","year":"2017","journal-title":"Chem Sci (Camb)"},{"key":"10.1124\/jpet.120.265181_bib64","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000328037","article-title":"Renal anemia of inflammation: the name is self-explanatory","volume":"32","author":"Yilmaz","year":"2011","journal-title":"Blood Purif"},{"key":"10.1124\/jpet.120.265181_bib65","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1021\/bi101585c","article-title":"Hypoxic induction of human erythroid-specific \u03b4-aminolevulinate synthase mediated by hypoxia-inducible factor 1","volume":"50","author":"Zhang","year":"2011","journal-title":"Biochemistry"},{"key":"10.1124\/jpet.120.265181_bib66","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1006\/abio.1999.4135","article-title":"Development of a carbon dioxide-capture assay in microtiter plate for aspartyl-beta-hydroxylase","volume":"271","author":"Zhang","year":"1999","journal-title":"Anal Biochem"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524258122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524258122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.120.265181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:42:02Z","timestamp":1739965322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524258122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0022356524258122"],"URL":"https:\/\/doi.org\/10.1124\/jpet.120.265181","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.120.265181","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s).","name":"copyright","label":"Copyright"}]}}